前列腺癌临床试验导航 | 海外癌症临床试验导航

适用疾病: Metastatic Castration-resistant Prostate Cancer (CRPC)；Metastatic Castration-resistant Prostate Carcinoma
干预: (R)-9bMS
地点: United States
申办方: TechnoGenesys, Inc.

即将招募 Phase 1 药物放疗

clinicaltrials.gov NCT07090369

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
干预: Olaparib (300 mg BID)，Pembrolizumab，177Lu-PSMA-I&T
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 3 药物

clinicaltrials.gov NCT05956639

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

适用疾病: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: 6-month course of antiandrogen drugs，Long-term course of antiandrogen drugs
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT07156045

Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer Castration-resistant Prostate Cancer
干预: anti-PSMA CAR-NK
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07529717

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: AZD8359，AZD8359，AZD8359，AZD8359
地点: United States，Australia，South Korea
申办方: AstraZeneca

正在招募 Phase 2 药物

clinicaltrials.gov NCT06844383

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

适用疾病: Prostate Cancer (Adenocarcinoma)；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: Talazoparib with enzalutamide，Talazoparib
地点: United States
申办方: Prostate Cancer Clinical Trials Consortium

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410494

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

适用疾病: Cancer；Breast Cancer；Non-Small Cell Lung Cancer (NSCLC)
干预: EB-SELECT Single-Target CAR-NK Cells，Dual-Target Antigen-Selected CAR-NK
地点: China
申办方: Essen Biotech

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT07226986

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

适用疾病: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
干预: AMO959，AAA617，Enzalutamide，Abiraterone
地点: United States，Australia，France，Germany 等 3 个
申办方: Novartis Pharmaceuticals

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT07649421

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

适用疾病: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: Stereotactic Body Radiotherapy (SBRT)，Darolutamide 600 mg twice daily，Androgen Deprivation Therapy (ADT)
地点: China
申办方: West China Hospital

正在招募 Phase 1 生物制剂药物手术/操作

clinicaltrials.gov NCT07219147

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Leukapheresis
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07310355

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: 68Ga-PSMA-0057，177Lu-PSMA-0057
地点: 未列出
申办方: Chengdu StarRay Therapeutics Co., Ltd

即将招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT07490210

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

适用疾病: Oligometastatic Prostate Cancer
干预: Metastasis-directed radiotherapy，Rezvilutamide + ADT，Radical prostatectomy
地点: China
申办方: Fudan University

正在招募 Phase 3 药物

clinicaltrials.gov NCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

适用疾病: Prostate Cancer Metastatic
干预: Opevesostat，Abiraterone acetate，Enzalutamide，Hydrocortisone
地点: United States，Argentina，Australia，Austria 等 32 个
申办方: Merck Sharp & Dohme LLC

正在招募阶段未标明药物手术/操作

clinicaltrials.gov NCT05649943

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

适用疾病: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: APA + ADT，Local Treatmetn RT or RP
地点: Italy
申办方: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT05104515

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

适用疾病: Prostate Cancer；Non Small Cell Lung Cancer；Ovarian Cancer
干预: OVM-200
地点: United Kingdom
申办方: Oxford Vacmedix UK Ltd.

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT06616155

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Bone Scan，Computed Tomography
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT07007910

Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: m CRPC
干预: HSK46575
地点: China
申办方: Haisco Pharmaceutical Group Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06683846

Ivonescimab in the Treatment of Multiple Advanced Tumors

适用疾病: Pheochromocytoma/Paraganglioma；Rhabdomyosarcoma；Paget Disease, Extramammary
干预: Ivocizumab
地点: China
申办方: Fudan University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT04704505

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

适用疾病: Prostate Adenocarcinoma；Metastatic Prostate Adenocarcinoma；Castration-resistant
干预: radium-223，Bipolar Androgen Therapy (BAT)
地点: United States，Brazil
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 基因治疗

clinicaltrials.gov NCT07543055

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

适用疾病: Prostate Cancer
干预: BPX-601
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07441889

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

适用疾病: Breast Cancer；Prostate Cancer
干预: HER2 FPBMC
地点: United States
申办方: University of Virginia

正在招募 Phase 1 药物

clinicaltrials.gov NCT06067841

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: BMS-986460
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07258407

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostatic Cancer
干预: TD001
地点: United States，Australia，Canada，France 等 1 个
申办方: T.O.A.D. Oncology SA

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT07298239

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)

适用疾病: Prostate Cancer Castration-resistant Prostate Cancer
干预: anti-PSMA CAR-NK
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1 药物

clinicaltrials.gov NCT07140900

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
干预: Xaluritamig，Darolutamide，Abiraterone
地点: United States，Australia，Switzerland
申办方: Amgen

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07514065

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy

适用疾病: Metastatic Castration-Resistant Prostate Cancer Patients
干预: Treatment arm: TSL2109 capsules。Oral administration。
地点: China
申办方: Tasly Pharmaceutical Group Co., Ltd

正在招募阶段未标明放疗

clinicaltrials.gov NCT04612907

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

适用疾病: Prostate Cancer；Radiotherapy Side Effect；Metastatic Cancer
干预: Moderate hypo-fractionation，Ultra-hypo-fractionation
地点: Sweden
申办方: Umeå University

正在招募 Phase 2 药物

clinicaltrials.gov NCT05011383

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

适用疾病: Metastatic Prostate Cancer
干预: High dose testosterone
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05521412

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer
干预: [ 161 Tb]Tb PSMA I&T
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

即将招募 Phase 2 药物

clinicaltrials.gov NCT07226713

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

适用疾病: Prostate Cancer
干预: Pacritinib
地点: United States
申办方: Medical College of Wisconsin

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07594106

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Clear Cell Renal Cell Carcinoma (ccRCC)
干预: REGN15505，REGN15505+Cemiplimab，REGN15505+REGN4336
地点: 未列出
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06084338

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

适用疾病: Prostate Cancer
干预: stereotactic ablative radiotherapy，Pluvicto，topical testosterone
地点: United States
申办方: VA Office of Research and Development

正在招募阶段未标明联合产品放疗

clinicaltrials.gov NCT04983095

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

适用疾病: Prostate Cancer Metastatic；Radiation Therapy；Positron-Emission Tomography
干预: stereotactic body radiotherapy，androgen deprivation therapy，Radiotherapy
地点: Sweden
申办方: Karin Soderkvist

即将招募 Phase 2 放疗

clinicaltrials.gov NCT07354594

External Beam and Radioligand Radiotherapy for mCRPC

适用疾病: Prostate Cancer Metastatic Castration-Resistant
干预: External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy，Standard of care 177Lutetium-PSMA
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

正在招募 Phase 2 药物

clinicaltrials.gov NCT07005154

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

适用疾病: Prostate Cancer；Metastatic Castration-Resistant Prostate Cancer；Metastatic Hormone Sensitive Prostate Cancer
干预: ASP5541，Prednisone，Prednisolone，abiraterone acetate
地点: United States，China，France，Germany 等 8 个
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07189403

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

适用疾病: Advanced or Metastatic Adrenocortical Carcinoma；Metastatic Castration-resistant Prostate Cancer
干预: DS9051b
地点: United States，France，United Kingdom
申办方: Daiichi Sankyo

正在招募 Phase 3 药物

clinicaltrials.gov NCT03851640

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

适用疾病: MCRPC
干预: HC-1119，placebo
地点: China
申办方: Hinova Pharmaceuticals Inc.

正在招募 Phase 3 药物

clinicaltrials.gov NCT04916613

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

适用疾病: Prostate Cancer Metastatic
干预: Darolutamide 300 mg，Placebo，Androgen deprivation therapy
地点: Belgium，France，Germany，Ireland 等 8 个
申办方: UNICANCER

即将招募 Phase 2 药物

clinicaltrials.gov NCT07623460

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: Zanzalintinib
地点: 未列出
申办方: Stuthi Perimbeti

即将招募 Phase 3 药物

clinicaltrials.gov NCT07591467

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer

适用疾病: BRCA-Mutated；Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer；Prostate Cancer
干预: Experimental
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

即将招募阶段未标明药物放疗

clinicaltrials.gov NCT06198387

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

适用疾病: Oligo-metastatic Prostate Carcinoma
干预: hormone and RT，ADT combined with abiraterone
地点: China
申办方: Changhai Hospital

即将招募 Phase 1 药物

clinicaltrials.gov NCT06866795

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

适用疾病: Metastatic Castration Resistant Prostate Cancer
干预: GT-220F capsule
地点: 未列出
申办方: Geode Therapeutics Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05113537

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Abemaciclib，Lutetium Lu 177-PSMA-617
地点: United States
申办方: Vadim S Koshkin

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06533644

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Partial Oncolysis，SV-102
地点: United States
申办方: Syncromune, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

适用疾病: Cervical Cancer；Breast Cancer；Colon Cancer
干预: ²¹²Pb-DOTAM-GRPR1
地点: United States
申办方: Orano Med Theranostics, SAS

即将招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06546527

Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）

适用疾病: Prostate Cancer
干预: [177Lu]Lu-PSMA-137
地点: 未列出
申办方: Peking University First Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07414940

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Prostate Cancer；Prostate Cancer
干预: Actinium (225Ac) rhPSMA-10.1
地点: United Kingdom
申办方: University College, London

正在招募 Phase 2 药物

clinicaltrials.gov NCT06059118

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: DFMO，testosterone cypionate，Luteinizing hormone-releasing hormone (LHRH) analogue，Enzalutamide
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07288359

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

适用疾病: Advanced HR+/HER2- Breast Cancer；Advanced CCNE1-amplified Solid Tumors；Metastatic Castration-resistant Prostate Cancer
干预: GVV858，Fulvestrant，Letrozole
地点: United States，Czechia，Denmark，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT01913106

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

适用疾病: Prostatic Neoplasms
干预: HSV-tk +Valacyclovir in Combination with Brachytherapy
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT05873192

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

适用疾病: Prostate Cancer
干预: ADT，Enzalutamide，Talazoparib，Degarelix
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物其他放疗

clinicaltrials.gov NCT06150417

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

适用疾病: Prostate Cancer；Malignant Neoplasm of Prostate；Secondary Malignant Neoplasm of Prostate
干预: Androgen deprivation therapy (ADT)，Androgen receptor signaling inhibitor (ARSI)，Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)，Metastasis directed radiotherapy (MDRT)
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 3 药物其他手术/操作

clinicaltrials.gov NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

适用疾病: Castration Levels of Testosterone；Metastatic Prostatic Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Abiraterone，Bicalutamide，Degarelix，Docetaxel
地点: United States，Chile，Colombia，Mexico 等 1 个
申办方: SWOG Cancer Research Network

正在招募 Phase 3 药物手术/操作

clinicaltrials.gov NCT06350825

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

适用疾病: Metastatic Prostate Cancer；Therapy, Directly Observed
干预: Cytoreductive prostatectomy or brachytherapy，ADT+second-generation antiandrogens ± chemotherapy
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06046040

TmPSMA-02 in mCRPC

适用疾病: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
干预: TmPSMA-02 CAR T Cells
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT06145633

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Bone Scan，Computed Tomography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT05563558

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

适用疾病: Prostate Cancer Metastatic
干预: Pembrolizumab，Carboplatin，Cabazitaxel
地点: Spain
申办方: Fundacion Oncosur

正在招募 Phase 2 药物

clinicaltrials.gov NCT06849544

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

适用疾病: Prostate Cancer Surgery；Prostate Cancer Metastatic Disease
干预: 0.03mg/kg ZOPOCIANINE given day of surgery，0.06mg/kg ZOPOCIANINE given day of surgery，0.03mg/kg ZOPOCIANINE given day prior to surgery，0.06mg/kg ZOPOCIANINE given days prior to surgery
地点: United States
申办方: Clinton Bahler

正在招募 Phase 2 药物

clinicaltrials.gov NCT04363164

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

适用疾病: Castration Resistant Metastatic Prostate Cancer
干预: Testosterone cypionate，Enzalutamide，Testosterone enanthate
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

clinicaltrials.gov NCT06830850

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration Resistant Prostate Cancer
干预: HRS-5041 Single dose of HRS-5041 orally administered
地点: Australia
申办方: Atridia Pty Ltd.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT02971358

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

适用疾病: Locally Advanced and Metastatic Prostate Cancer
干预: Radical prostatectomy
地点: Austria
申办方: Medical University of Vienna

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07172126

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: TQB3201 tablets
地点: China
申办方: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

适用疾病: Cancer；Solid Tumor Cancer；Advanced Metastatic Cancer
干预: SYS6043
地点: United States
申办方: Conjupro Biotherapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07292168

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

适用疾病: Renal Cell Carcinoma Metastatic；Prostate Cancer Metastatic；Non-small Cell Lung Cancer Metastatic
干预: humanized monoclonal anti-FGFR1 antibody OM-RCA-01
地点: Russia
申办方: Kidney Cancer Research Bureau

正在招募 Phase 3 药物

clinicaltrials.gov NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)；Prostatic Neoplasms
干预: Opevesostat，Dexamethasone，Fludrocortisone acetate，Hydrocortisone
地点: United States，Australia，Brazil，Canada 等 35 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07332455

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

适用疾病: Neoplasms, Prostate
干预: GSK5471713
地点: United States，Canada，Japan，South Korea
申办方: GlaxoSmithKline

正在招募 Phase 2 药物

clinicaltrials.gov NCT06957691

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

适用疾病: Prostate Cancer；Prostate Cancer (Adenocarcinoma)；Prostate Cancer Metastatic Disease
干预: fezolinetant - reference formulation，Placebo
地点: United States
申办方: Shehzad Basaria, M.D.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05489211

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

适用疾病: Endometrial Cancer；Gastric Cancer；Metastatic Castration-resistant Prostate Cancer
干预: Datopotamab deruxtecan (Dato-DXd)，Capecitabine，5-Fluorouracil，Volrustomig
地点: United States，Canada，China，France 等 10 个
申办方: AstraZeneca

正在招募 Phase 3 药物

clinicaltrials.gov NCT06925737

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

适用疾病: Prostate Cancer；Prostatic Neoplasms
干预: Ifinatamab deruxtecan，Docetaxel，Prednisone，Rescue Medication
地点: United States，Argentina，Australia，Austria 等 31 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06480110

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Docetaxel + Ebastine，Docetaxel
地点: Denmark
申办方: Rigshospitalet, Denmark

正在招募 Phase 2 生物制剂

clinicaltrials.gov NCT06347705

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

适用疾病: Prostate Cancer
干预: 2141-V11 Antibody
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT07250542

A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: Fasudil hydrochloride combined with immunotherapy
地点: China
申办方: baotai Liang

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07002320

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
干预: SX-682，Apalutamide
地点: Switzerland，United Kingdom
申办方: Institute of Cancer Research, United Kingdom

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07190300

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

适用疾病: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: Tulmimetostat，Darolutamide，Abiraterone
地点: United States，Australia，Brazil，Canada 等 10 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

clinicaltrials.gov NCT05818683

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Neoplasms；Metastatic Hormone-sensitive Prostate Cancer
干预: Pasritamig，Cetrelimab，Cabazitaxel，Docetaxel
地点: United States，Australia，Spain
申办方: Janssen Research & Development, LLC

正在招募 Phase 2 药物

clinicaltrials.gov NCT03833921

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

适用疾病: Prostate Cancer Metastatic；Prostate Cancer
干预: Abiraterone Acetate，Prednisone
地点: United States
申办方: Martha Mims

正在招募 Phase 2 药物

clinicaltrials.gov NCT06971211

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.
地点: China
申办方: Jianbin Bi

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04633252

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

适用疾病: Cancer Of Prostate；Prostate Neoplasms
干预: PDS01ADC，Docetaxel，M7824，Prednisone
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 药物

clinicaltrials.gov NCT07225946

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostatic Neoplasms, Castration-Resistant
干预: Pasritamig，Docetaxel，Prednisone
地点: United States，Australia，Belgium，Brazil 等 13 个
申办方: Janssen Research & Development, LLC

即将招募 EARLY / Phase 1 药物放疗

clinicaltrials.gov NCT07674771

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

适用疾病: Castrate Sensitive Prostate Cancer；Prostate Cancer；Metastasis Castration Resistant Prostate Cancer(mCRPC)
干预: Drug: 68-Ga PSMA11，Adaptive stereotactic ablative radiotherapy (SABR)，68Ga-PSMA-11，Adaptive stereotactive ablative radiotherapy (SABR)
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07590934

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: AZD2265 (FPI-2265)，AZD9574，Docetaxel，AZD2287 (Imaging agent)
地点: United States，Australia，Germany，Italy 等 3 个
申办方: AstraZeneca

正在招募 Phase 2 药物

clinicaltrials.gov NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Tumor；Melanoma；Head and Neck Cancer
干预: HER3-DXd
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Daiichi Sankyo

正在招募 Phase 3 药物

clinicaltrials.gov NCT07241416

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
干预: Rezvilutamide Tablets，Enzalutamide Soft Capsules
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06784193

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

适用疾病: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)；Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)；Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: OP-3136，Fulvestrant，Palazestrant
地点: United States，Australia
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT06244004

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

适用疾病: Castration-Sensitive Prostate Carcinoma；Metastatic Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Antiandrogen Therapy，Bone Scan，Computed Tomography，Cytotoxic Chemotherapy
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT07650240

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

适用疾病: Recurrent Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8；Castration-Sensitive Prostate Cancer
干预: Abiraterone Acetate，Biospecimen Collection，Leuprolide Acetate，Lutetium Lu 177 Vipivotide Tetraxetan
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT06249750

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (CRPC)
干预: Immunotherapy，Targeted therapy，Hyperthermia
地点: China
申办方: Pengyuan Liu

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05223803

TERPS Trial for de Novo Oligometastic Prostate Cancer

适用疾病: Prostate Cancer；Oligometastatic Disease
干预: Prostate radiation (XRT)，Systemic Therapy，Stereotactic ablative radiation therapy (SABR)
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT06193486

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: MSGV1-PSCA-8T28Z，Fludarabine，Cyclophosphamide
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT05743621

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostatic Neoplasms, Castration-Resistant
干预: TVB-2640，Enzalutamide
地点: United States
申办方: Weill Medical College of Cornell University

即将招募 Phase 1 药物

clinicaltrials.gov NCT06614751

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

适用疾病: Solid Cancers；BRCA Mutation；HRD Cancer
干预: DAT-2645 tablet，DAT-2645 tablet
地点: China
申办方: Danatlas Pharmaceuticals Co., Ltd

正在招募 Phase 2 药物

clinicaltrials.gov NCT06866938

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
地点: France
申办方: Hospices Civils de Lyon

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06155084

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: HP518 - Dose Escalation，HP518 - Dose Escalation，HP518 -Dose Expansion
地点: China
申办方: Hinova Pharmaceuticals Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 药物

clinicaltrials.gov NCT07493512

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: Xaluritamig
地点: United States
申办方: Amgen

正在招募 Phase 2, Phase 3 药物其他手术/操作

clinicaltrials.gov NCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

适用疾病: Prostate Cancer；Oligometastasis；Oligorecurrence
干预: PET-directed Local Therapy using Surgery，PET-directed Local Therapy using Radiation，Salvage Local Therapy for locally recurrent disease，Goserelin, Histrelin, Leuprolide & Triptorelin
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1 生物制剂手术/操作放疗

clinicaltrials.gov NCT05805371

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes，Biopsy，Biospecimen Collection，Bone Scan
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT07537010

3D1015 Injection for Patients With mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer, mCRPC
干预: Lu 177-PSMA-3D1015 Injection
地点: China
申办方: Chunjing Yu

正在招募 Phase 2 药物

clinicaltrials.gov NCT06738303

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

适用疾病: Metastatic Prostate Cancer；Metastatic Castration-resistant Prostate Cancer
干预: Cabazitaxel and carboplatin，Lu-PSMA-617
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT05762536

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Darolutamide，Docetaxel or cabazitaxel
地点: Netherlands
申办方: Erasmus Medical Center

正在招募阶段未标明放疗

clinicaltrials.gov NCT06978296

HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

适用疾病: Prostate Cancer Metastatic Disease；Oligometastatic Prostate Cancer (OMPC)
干预: Stereotactic body radiotherapy (SBRT)
地点: France
申办方: Institut Cancerologie de l'Ouest

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Castration-resistant Prostate Cancer
干预: JANX014
地点: United States
申办方: Janux Therapeutics

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07189871

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

即将招募 EARLY / Phase 1 Dietary_Supplement药物

clinicaltrials.gov NCT07389187

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

适用疾病: mCRPC
干预: LC-K76，Tislelizumab，Standard Androgen Deprivation Therapy (ADT)
地点: China
申办方: Shanghai Changzheng Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07135102

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Cancer Patients
干预: 225Ac-PSMA-XT
地点: China
申办方: Xiaorong Sun

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT06992232

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

适用疾病: Prostate Cancer Metastatic Disease
干预: Intense androgen deprivation therapy，Radiation Therapy，radical prostatectomy
地点: China
申办方: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

正在招募 Phase 2 药物

clinicaltrials.gov NCT06134232

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: Sipuleucel-T Injection
地点: United States
申办方: Dendreon

正在招募 Phase 1 药物

clinicaltrials.gov NCT07503808

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 2, Phase 3 药物放疗

clinicaltrials.gov NCT07426055

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

适用疾病: Prostate Cancer (Adenocarcinoma)；Prostate Brachytherapy；Stereotactic Body Radiation Therapy (SBRT)
干预: Stereotactic Body Radiotherapy (SBRT) Monotherapy，External Beam Radiotherapy (EBRT) Backbone，High-Dose-Rate Brachytherapy Boost，Low-Dose-Rate Brachytherapy Boost
地点: Poland
申办方: Affidea Nu-med Center of Oncological DIagnostics and Therapy

正在招募 Phase 1 药物

clinicaltrials.gov NCT07570979

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: INR731，Enzalutamide，Abiraterone，Androgen deprivation therapy (ADT)
地点: United States，Australia
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03972657

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Clear Cell Renal Cell Carcinoma (ccRCC)
干预: REGN5678，Cemiplimab
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT06236139

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Anti-STEAP1 CAR T-cells，Biopsy Procedure，Biospecimen Collection，Bone Scan
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募阶段未标明放疗

clinicaltrials.gov NCT04838899

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

适用疾病: Oligoprogressive；Castration-Resistant Prostate Cancer
干预: Stereotactic Body Radiation Therapy (SABR)
地点: Canada
申办方: Sunnybrook Health Sciences Centre

正在招募 Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT03866382

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

适用疾病: Bladder Adenocarcinoma；Bladder Clear Cell Adenocarcinoma；Bladder Mixed Adenocarcinoma
干预: Biospecimen Collection，Bone Scan，Cabozantinib S-malate，Computed Tomography
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07641855

A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

适用疾病: Castration-resistant Prostate Cancer
干预: BL-B01D1，Abiraterone，Olaparib
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06827080

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer, MCRPC；Cancer
干预: 30 mCi NYMO32，50 mCi NYMO32，80 mCi NYMO32，130 mCi NYMO32
地点: 未列出
申办方: Zhengguo Chen

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07192120

A Study of MHB048C in Patients With Advanced Solid Tumors

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)；Advanced Malignant Solid Tumor
干预: MHB048C for Injection
地点: China
申办方: Minghui Pharmaceutical (Hangzhou) Ltd

正在招募 Phase 2 药物

clinicaltrials.gov NCT06568562

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: XL092
地点: United States
申办方: University of Utah

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06854250

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: Prostate cryoablation，Cyclophosphamide (CTX)
地点: China
申办方: Sun Yat-sen University

即将招募 Phase 1 药物放疗

clinicaltrials.gov NCT07316686

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

适用疾病: Prostate Cancer (Adenocarcinoma)
干预: Docetaxel 50mg/m2，Docetaxel 60mg/m2，Docetaxel 75 mg/m²，177Lu-PSMA-I&T
地点: Brazil
申办方: Instituto do Cancer do Estado de São Paulo

正在招募 Phase 3 药物

clinicaltrials.gov NCT07311694

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

适用疾病: PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
干预: HRS-4357 injection，Enzalutamide；Abiraterone
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募阶段未标明放疗

clinicaltrials.gov NCT05209243

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

适用疾病: Prostate Cancer；Stereotactic Body Radiation Therapy
干预: SBRT，STANDARD OF CARE
地点: Spain
申办方: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

即将招募 Phase 4 药物

clinicaltrials.gov NCT06660862

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

适用疾病: Prostate Cancer
干预: Darolutamide，Physician choice Androgen Deprivation (Hormone) Therapy
地点: United States
申办方: University of Chicago

正在招募 Phase 1 药物

clinicaltrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06594926

Working Out M0 Bipolar Androgen Therapy

适用疾病: Prostate Cancer
干预: Testosterone Enanthate
地点: Australia
申办方: Australian and New Zealand Urogenital and Prostate Cancer Trials Group

即将招募 Phase 1 药物

clinicaltrials.gov NCT07423117

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

适用疾病: Metastatic Castration-resistant Prostate Cancer；Non-small Cell Lung Cancer；Triple Negative Breast Cancer
干预: ITC-6146RO
地点: 未列出
申办方: IntoCell, Inc

正在招募 Phase 3 药物

clinicaltrials.gov NCT06177015

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

适用疾病: Metastatic Prostate Cancer；Intermitent Anti-androgen Therapy
干预: Darolutamide continuous，Darolutamide intermittent
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

适用疾病: Advanced Solid Tumor；Diffuse Large B Cell Lymphoma；Lymphoma, T-Cell
干预: Tulmimetostat，Enzalutamide
地点: United States，France，Italy，Poland 等 3 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06800313

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: HLD-0915 Hard Capsule，HLD-0915 Tablet，HLD-0915 Soft Capsule
地点: United States，United Kingdom
申办方: Halda Therapeutics OpCo, Inc.

即将招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT07381582

Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

适用疾病: Prostate Cancer
干预: 161Tb-LNC1011
地点: China
申办方: Peking Union Medical College Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT05422911

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

适用疾病: Metastatic Cancer；Neoplasm, Prostate；Castrate-sensitive
干预: Abiraterone acetate，Apalutamide，Enzalutamide
地点: United States
申办方: Sun Pharmaceutical Industries Limited

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05720130

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Metastatic Hormone Sensitive Prostate Cancer
干预: [²¹²Pb]Pb-ADVC001 (Phase 1b)，[²¹²Pb]Pb-ADVC001 (Phase 2a)
地点: Australia
申办方: AdvanCell Pty Limited

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06190899

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)；Genital Diseases, Male；Urogenital Diseases, Male
干预: Gedatolisib，Darolutamide
地点: United States，France，Spain，United Kingdom
申办方: Celcuity Inc

即将招募 Phase 2 药物

clinicaltrials.gov NCT07608718

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Zanzalintinib
地点: United States
申办方: Pedro Barata, MD, MSc

正在招募 Phase 3 药物

clinicaltrials.gov NCT05939414

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

适用疾病: Oligometastatic Prostate Cancer (OMPC)
干预: AAA617
地点: United States，Argentina，Australia，Austria 等 23 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

clinicaltrials.gov NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07581184

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Castration Resistant Metastatic Prostate Cancer；Prostate Cancer；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: [225Ac]Ac-AKY-2519 (therapeutic)，[64Cu]Cu-AKY-2519 (imaging)
地点: United States
申办方: Aktis Oncology, Inc.

正在招募 Phase 3 药物

clinicaltrials.gov NCT07213674

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Xaluritamig，Abiraterone acetate，Docetaxel，Cabazitaxel
地点: United States，Australia，Austria，Belgium 等 14 个
申办方: Amgen

正在招募 Phase 4 药物

clinicaltrials.gov NCT05348876

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

适用疾病: Non-metastatic Castration-resistant Prostate Cancer
干预: Darolutamide (Nubeqa, BAY1841788)
地点: India
申办方: Bayer

即将招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT07268794

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

适用疾病: Metastatic Prostate Cancer；Prostate Cancer (Adenocarcinoma)；Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: Androgen Deprivation Therapy (ADT)，Docetaxel，PARP Inhibitors and Other Systemic Agents，Radical Prostatectomy
地点: China
申办方: Fudan University

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT05519449

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Castration Resistant Prostatic Cancer
干预: JANX007，Darolutamide
地点: United States，Australia
申办方: Janux Therapeutics

正在招募 Phase 2 药物

clinicaltrials.gov NCT06100705

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Testosterone Cypionate，Sipuleucel-T
地点: United States
申办方: Yale University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06966024

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

适用疾病: Renal Cell Carcinoma；Urothelial Carcinoma；Castration-resistant Prostate Cancer
干预: DCC-2812
地点: United States
申办方: Deciphera Pharmaceuticals, LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06970119

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

适用疾病: Prostate Cancer
干预: INR102 injection
地点: China
申办方: Yunhe Pharmaceutical (Tianjin) Co., Ltd

正在招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT06632977

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

适用疾病: Castration-Resistant Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Genetic testing，Valemetostat Tosylate，Magnetic Resonance Imaging，Computed Tomography
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 1 药物

clinicaltrials.gov NCT06343038

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

适用疾病: Castration-resistant Prostate Cancer
干预: Injection, 161Tb-SibuDAB,1GBq，Injection, 177Lu-PSMA-I&T, 1GBq，Injection, 161Tb-SibuDAB, Dose Escalation
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 1 药物

clinicaltrials.gov NCT06531499

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: AAA617，Gonadotropin-releasing hormone (GnRH) analogues，Gonadotropin-releasing hormone (GnRH) antagonists
地点: United States，Germany，Netherlands，Spain 等 2 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

clinicaltrials.gov NCT07339267

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

适用疾病: Prostate Cancer；Metastatic Castration-Resistant Prostate Cancer；Metastatic Hormone Sensitive Prostate Cancer
干预: ASP5541，Prednisone
地点: China
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07540572

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

适用疾病: ER+, HER 2- Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Castration-resistant Prostate Cancer (CRPC)
干预: IDE574，Fulvestrant injection
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

clinicaltrials.gov NCT06801236

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer (Adenocarcinoma)；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: ACE-232 tablets
地点: United States
申办方: Acerand Therapeutics (Hong Kong) Limited

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT06267729

Study of AZD0754 in Participants With Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: AZD0754，AZD2287
地点: United States，Australia，Spain
申办方: AstraZeneca

正在招募 Phase 2 联合产品放疗

clinicaltrials.gov NCT07451795

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

适用疾病: Prostate Cancer；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: SHR-1701 + SBRT，SBRT
地点: China
申办方: Fudan University

正在招募 Phase 3 生物制剂药物其他

clinicaltrials.gov NCT07164443

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

适用疾病: Metastatic Castration-resistant Prostate Neoplasms
干预: Pasritamig，Placebo，Best Supportive Care (BSC)
地点: United States，Australia，Belgium，Brazil 等 13 个
申办方: Janssen Research & Development, LLC

正在招募阶段未标明药物放疗

clinicaltrials.gov NCT07483658

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

适用疾病: Reccurent/Metastatic Solid Tumor Disease；Prostate Cancer (Post Prostatectomy)；Prostate Cancer
干预: Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions)，Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions)，Androgen Deprivation Therapy (ADT)
地点: Canada
申办方: CHU de Quebec-Universite Laval

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT07477626

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

适用疾病: Prostate Cancer (Post Prostatectomy)；Radiotherapy; Image-Guided；Prostate Cancer Non-Metastatic
干预: Androgen Deprivation Therapy (ADT)，radiotherapy
地点: China
申办方: Sun Yat-sen University

即将招募 Phase 2 药物

clinicaltrials.gov NCT06505278

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

适用疾病: Prostate Cancer
干预: Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 2 其他放疗

clinicaltrials.gov NCT06927635

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

适用疾病: Castrate Resistance Prostate Cancer；OligoProgressive Metastatic Disease
干预: Stereotactic Body Radiation Therapy (SBRT)，Systemic therapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06689163

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

适用疾病: Prostate Cancer
干预: HRS-1167 tablets，Abiraterone Acetate tablets（II），Prednisone Acetate tablets
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

即将招募 Phase 3 药物

clinicaltrials.gov NCT06768255

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

适用疾病: Abiraterone Acetate；MCRPC (metastatic Castration-resistant Prostate Cancer)
干预: Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT，Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
地点: China
申办方: Ding-Wei Ye

正在招募 Phase 1 药物

clinicaltrials.gov NCT07660211

Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）

适用疾病: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: 177Lu-PSMA-VG01
地点: China
申办方: VitsGen Therapeutics Inc.

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06832774

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

适用疾病: Prostate Cancer Metastatic Disease
干预: Local treatment，Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
地点: China
申办方: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

正在招募 Phase 3 药物

clinicaltrials.gov NCT06439225

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Prostate Cancer
干预: Docetaxel，Carboplatin
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT04550494

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

clinicaltrials.gov NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT06401980

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Darolutamide，Standard of care
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 1, Phase 2 诊断检测药物

clinicaltrials.gov NCT04946370

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: 225Ac-J591，Pembrolizumab，Androgen receptor inhibitor，68Ga-PSMA-11
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1 药物放疗

clinicaltrials.gov NCT04235777

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

适用疾病: Urothelial Cancer；Bladder Cancer；Genitourinary Cancer
干预: Stereotactic body radiation therapy (SBRT)，PDS01ADC，M7824
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

clinicaltrials.gov NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

适用疾病: Metastatic Solid Tumor；Recurrent Solid Tumor；Advanced Solid Tumor
干预: LY4052031
地点: United States，Australia，China，France 等 4 个
申办方: Eli Lilly and Company

即将招募 Phase 3 药物

clinicaltrials.gov NCT07632690

QLC5508 in Participants With Metastatic Prostate Cancer

适用疾病: Prostate Cancer
干预: QLC5508，Docetaxel
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT07344311

A Phase I Trial of A-CAR032 in Participants With mCRPC

适用疾病: Prostate Cancer；Metastatic Castration-Resistant Prostate Cancer
干预: dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection
地点: China
申办方: Shanghai AbelZeta Ltd.

正在招募 Phase 1 药物手术/操作

clinicaltrials.gov NCT06492122

Study With [225Ac]Ac-FL-020 in mCRPC Participants

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: [225Ac]Ac-FL-020，Blood samples for PK，[111In]In-FL-020，Blood and urine samples collection
地点: United States，Australia，China，Turkey (Türkiye)
申办方: Full-Life Technologies UK Limited

即将招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT05717582

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

适用疾病: Metastatic Prostate Cancer；Castration-Sensitive Prostate Cancer
干预: apalutamide，androgen deprivation therapy，cytoreductive radical prostatectomy with/without pelvic lymph node dissection，metastasis-directed therapy with radiation
地点: China
申办方: Fudan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07179783

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

适用疾病: Prostate Cancer (Adenocarcinoma)；Prostate Cancer Metastatic Castration-Resistant；Prostate Adenocarcinoma With Neuroendocrine Differentiation
干预: Sacituzumab Tirumotecan，Tagitanlimab
地点: China
申办方: Tianjin Medical University Second Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06592924

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

适用疾病: Prostate Cancer (Adenocarcinoma)
干预: Abiraterone，Enzalutamide，Apalutamide，Darolutamide (BAY 1841788)
地点: United States，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 2 药物

clinicaltrials.gov NCT06616597

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

适用疾病: Prostate Cancer (Adenocarcinoma)；Metastatic Prostate Cancer
干预: Abiraterone acetate，Dexamethasone，Metronidazole
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

clinicaltrials.gov NCT06879041

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: AZD2287，AZD2275，AZD2284
地点: United States，Australia，South Africa
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06863272

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

适用疾病: Castration-Resistant Prostatic Cancer；Metastasis
干预: Docetaxel，Ifinatamab Deruxtecan，MK-5684，Abiraterone
地点: United States，Argentina，Australia，Brazil 等 15 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07567521

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

适用疾病: Prostate Cancer
干预: Radiopharmaceuticals
地点: China
申办方: C Ray Therapeutics

正在招募 Phase 2 药物

clinicaltrials.gov NCT07287150

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: Inavolisib，Enzalutamide，Abiraterone，Docetaxel
地点: United States，Australia，Brazil，Canada 等 7 个
申办方: Hoffmann-La Roche

正在招募 Phase 3 药物其他放疗

clinicaltrials.gov NCT06320067

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

适用疾病: Prostate Cancer Metastatic
干预: Stereotactic Ablative Body Radiotherapy (SABR)，177Lu-PSMA-617，Androgen Deprivation Therapy (ADT)，Androgen Receptor Signalling Inhibitor (ARPI)
地点: United Kingdom
申办方: University College, London

即将招募 Phase 2 药物

clinicaltrials.gov NCT06890832

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer, MCRPC
干预: 50 mg cabazitaxel，100 mg cabazitaxel，200 mg cabazitaxel
地点: 未列出
申办方: Jina Pharmaceuticals Inc.

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07104617

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: TY-302，Abiraptor
地点: China
申办方: TYK Medicines, Inc

正在招募 Phase 2 药物

clinicaltrials.gov NCT07142551

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Testosterone cypionate，Luteinizing hormone-releasing hormone (LHRH) analogue，Darolutamide
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

clinicaltrials.gov NCT07216248

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
干预: relugolix + ARPI，Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI，relugolix or androgen deprivation therapy (ADT) + ARPI，relugolix + ARPI.
地点: United States
申办方: University of Utah

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07104643

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

适用疾病: mCRPC
干预: TYK-00540，Enzalutamide
地点: China
申办方: TYK Medicines, Inc

即将招募阶段未标明放疗

clinicaltrials.gov NCT07635108

MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)

适用疾病: Prostate Cancer；Oligo-metastatic Prostate Carcinoma；Oligometastatic Cancer
干预: Single-fraction SBRT
地点: Denmark
申办方: Odense University Hospital

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT05603559

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: 1.1 GBq (30 mCi) of 177Lu-P17-087，1.1 GBq (30 mCi) of 177Lu-P17-088
地点: China
申办方: Peking Union Medical College Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07336446

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

适用疾病: Prostate Cancer
干预: AZD9750，AZD5305
地点: United States，Australia，Canada，China 等 4 个
申办方: AstraZeneca

正在招募 Phase 1 药物

clinicaltrials.gov NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

适用疾病: Metastatic Castration Resistant Prostate Cancer (mCRPC)；Small Cell Lung Cancer (SCLC)；Follicular Lymphoma (FL)
干预: Mervometostat (PF-06821497)，Enzalutamide，Itraconazole
地点: United States，Bulgaria，China，Japan 等 4 个
申办方: Pfizer

即将招募 Phase 2 药物

clinicaltrials.gov NCT04925063

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

适用疾病: Metastatic Prostate Cancer
干预: Metformin
地点: China
申办方: Sun Yat-sen University

即将招募 Phase 3 药物

clinicaltrials.gov NCT07598032

Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression

适用疾病: Prostate Cancer (Adenocarcinoma)；Vitamin D on Tumor Response and Inflammatory Markers
干预: vitamin D 25(OH)D
地点: Nigeria
申办方: University of Ilorin Teaching Hospital

正在招募 Phase 2 其他放疗

clinicaltrials.gov NCT05457699

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

适用疾病: Prostate Cancer Metastatic
干预: Metastasis directed radiotherapy (MDRT)，no MDRT
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

正在招募 Phase 2 药物

clinicaltrials.gov NCT06842498

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: FG-3246
地点: United States
申办方: Kyntra Bio

即将招募 Phase 2 药物

clinicaltrials.gov NCT07310433

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

适用疾病: Prostate Cancer；Metastatic Prostate Cancer
干预: Dapagliflozin (10mg Tab)，standard medical care (ADT + NHA)
地点: China
申办方: Yung NA

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06782555

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

适用疾病: Metastatic Prostate Cancer；Metastatic Head and Neck Squamous Cell Carcinoma；Metastatic Pancreatic Cancer
干预: Evofosfamide，Zalifrelimab，Balstilimab
地点: United States
申办方: ImmunoGenesis

正在招募阶段未标明放疗

clinicaltrials.gov NCT06462963

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

适用疾病: Breast Cancer；Prostate Cancer；NSCLC
干预: single-fraction SBRT，multiple-fraction SBRT
地点: Belgium，Italy，Netherlands，Switzerland
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 1 药物

clinicaltrials.gov NCT07103018

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Castration-Resistant Prostate Cancer Patients；Metastatic Castration-resistant Prostate Cancer, mCRPC
干预: KTX-2001，KTX-2001 + Darolutamide (NUBEQA®)
地点: United States
申办方: K36 Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07363486

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: 225Ac-LNC1011
地点: China
申办方: First Affiliated Hospital of Fujian Medical University

正在招募 Phase 1 药物

clinicaltrials.gov NCT07181473

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

适用疾病: Lung Cancer (NSCLC)；Prostate Cancer；Esophageal Cancer
干预: TJ101
地点: United States，China
申办方: Phrontline Biopharma

正在招募 Phase 3 药物

clinicaltrials.gov NCT07028853

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

适用疾病: Metastatic Castration Sensitive Prostate Cancer (mCSPC)；Hormone Sensitive Prostate Cancer；Prostate Cancer
干预: Mevrometostat，Placebo，Enzalutamide
地点: United States，Argentina，Australia，Belgium 等 22 个
申办方: Pfizer

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07255664

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

适用疾病: Metastatic Colorectal Cancer；Prostate Cancer Metastatic；Prostate Cancer Locally Advanced
干预: CC-38，Pembrolizumab，Cyclophosphamid，Interleukin-2
地点: Germany
申办方: CuraCell TX AB

正在招募 Phase 1 药物

clinicaltrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07244341

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Valemetostat，Darolutamide
地点: United States，China，Ireland，Japan
申办方: Daiichi Sankyo

正在招募 Phase 2 药物

clinicaltrials.gov NCT04606446

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

适用疾病: Locally Advanced or Metastatic ER+ HER2- Breast Cancer；Locally Advanced or Metastatic Castration-resistant Prostate Cancer；Locally Advanced or Metastatic Non-small Cell Lung Cancer
干预: PF-07248144，Fulvestrant，Letrozole，Palbociclib
地点: United States，Australia，China，Japan 等 1 个
申办方: Pfizer

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT07645326

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
干预: Androgen Deprivation Therapy (ADT)，Androgen Receptor Pathway Inhibitor (ARPI)，Prostate Radiation，Docetaxel
地点: United States
申办方: Georgetown University

即将招募 Phase 1 药物

clinicaltrials.gov NCT06099990

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

适用疾病: High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
干预: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets，placebo; abiraterone acetate tablets; prednisone tablets
地点: 未列出
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06654336

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

适用疾病: Prostate Adenocarcinoma；Castration Sensitive Prostate Cancer
干预: Recurrence-directed therapy (RDT)，ELIGARD 22.5mg
地点: Canada
申办方: Ontario Clinical Oncology Group (OCOG)

正在招募 Phase 2 药物

clinicaltrials.gov NCT05534646

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

适用疾病: Castration-resistant Prostate Cancer
干预: Apalutamide，Carotuximab
地点: United States
申办方: Edwin Posadas, MD

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06990880

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

适用疾病: Neoplasms, Prostate
干预: GSK5458514
地点: United States，Canada，France，Japan 等 1 个
申办方: GlaxoSmithKline

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06702995

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castrate-Resistant Prostate Cancer；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: XNW5004，enzalutamide
地点: China
申办方: Evopoint Biosciences Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06228053

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: SX-682，Enzalutamide
地点: United States
申办方: Syntrix Biosystems, Inc.

即将招募 Phase 2 药物

clinicaltrials.gov NCT06738745

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

适用疾病: Prostate Cancer Metastatic Disease
干预: HRS-2189，HRS-5041
地点: China
申办方: Fudan University

正在招募 Phase 1 药物

clinicaltrials.gov NCT04221542

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: AMG 509，Abiraterone，Enzalutamide
地点: United States，Australia，China，Germany 等 6 个
申办方: Amgen

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05896371

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

适用疾病: Cancer；Prostate Cancer；Metastatic Cancer
干预: 177Lu-PSMA-I&T - escalating renal absorbed dose，177Lu-PSMA-I&T - recommended phase 2 regime
地点: 未列出
申办方: CHU de Quebec-Universite Laval

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06655259

Combination of TURP and Standard Systemic Therapy for MPCa

适用疾病: Metastatic Prostate Cancer
干预: TURP，Standard Medical Therapy
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06353386

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

适用疾病: Prostatic Neoplasms, Castration-Resistant
干预: Opevesostat，Olaparib，Docetaxel，Cabazitaxel
地点: United States，Australia，Canada，Chile 等 16 个
申办方: Merck Sharp & Dohme LLC

即将招募 Phase 2 生物制剂

clinicaltrials.gov NCT07024277

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

适用疾病: Neuroendocrine Prostate Cancer
干预: ZG006
地点: China
申办方: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05125016

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: REGN4336，REGN5678
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1 联合产品药物

clinicaltrials.gov NCT05997615

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

适用疾病: Hormone-refractory Prostate Cancer
干预: VIR-5500，ARSI
地点: United States，Australia，Spain，United Kingdom
申办方: Vir Biotechnology, Inc.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06582017

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

适用疾病: Ovarian Cancer；Pancreas Cancer；Urothelial Carcinoma
干预: QXL138AM Injection every 2 weeks by IV Infusion
地点: United States
申办方: Nammi Therapeutics Inc

正在招募 Phase 1 药物

clinicaltrials.gov NCT04886986

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: 225Ac-J591，177Lu-PSMA-617，68Ga-PSMA-11，177Lu-PSMA-I&T
地点: United States
申办方: Weill Medical College of Cornell University

即将招募 Phase 1 药物

clinicaltrials.gov NCT07468396

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

适用疾病: Prostate Cancer
干预: GLR2037
地点: China
申办方: Gan & Lee Pharmaceuticals.

正在招募 Phase 2 药物

clinicaltrials.gov NCT04986423

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: ZEN003694，Enzalutamide
地点: United States，China
申办方: Zenith Epigenetics

正在招募 Phase 2 放疗

clinicaltrials.gov NCT05656794

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

适用疾病: Prostate Metastases
干预: Radiotherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募阶段未标明药物手术/操作

clinicaltrials.gov NCT06306612

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

适用疾病: Prostate Cancer
干预: Systemic Chemohormonal Therapy，Systemic Hormonal Therapy，Cytoreductive Prostatectomy，Postoperative Adjuvant Radiotherapy
地点: China
申办方: RenJi Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT06943495

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
干预: 177Lu-PSMA-617，177Lu-PSMA-617
地点: Canada
申办方: Jean-Mathieu Beauregard

正在招募 Phase 3 药物

clinicaltrials.gov NCT05983783

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

适用疾病: Metastatic Prostate Cancer；Hormone Sensitive Prostate Cancer；Chemotherapy Effect
干预: Docetaxel，Rezvilutamide
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

即将招募 Phase 1 手术/操作放疗

clinicaltrials.gov NCT06982222

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Positron Emission Tomography
地点: 未列出
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

clinicaltrials.gov NCT06666270

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Cancer；Metastatic Solid Tumor；Ovarian Cancer
干预: SYN818
地点: China
申办方: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

正在招募阶段未标明联合产品

clinicaltrials.gov NCT07172685

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

适用疾病: Prostate Cancer
干预: Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy
地点: China
申办方: Qilu Hospital of Shandong University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

适用疾病: Advanced Solid Tumor；Advanced Malignant Neoplasm；Metastatic Cancer
干预: rezatapopt，pembrolizumab
地点: United States，Australia，France，Germany 等 5 个
申办方: PMV Pharmaceuticals, Inc

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06785636

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)；Prostate Cancer
干预: Pocenbrodib，Pocenbrodib and Darolutamide
地点: United States
申办方: Pathos AI, Inc.

正在招募 Phase 3 药物

clinicaltrials.gov NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: BNT324，Docetaxel，Prednisone/prednisolone
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06663007

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

适用疾病: Prostate Cancer；CDK12 Gene Mutation
干预: RC48，Envafolimab
地点: China
申办方: Tianjin Medical University Second Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06001255

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

适用疾病: Metastasis Castration Resistant Prostate Cancer(mCRPC)
干预: HS-20093
地点: China
申办方: Hansoh BioMedical R&D Company

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06609005

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

适用疾病: Advanced Metastatic Castration Resistant Prostate Cancer
干预: INV-9956
地点: United States，China
申办方: Shenzhen Ionova Life Sciences Co., Ltd.

正在招募阶段未标明药物

clinicaltrials.gov NCT05613738

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01，1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01，2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
地点: China
申办方: Peking Union Medical College Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06610825

Castrate Resistant Prostate Cancer Enhertu Therapy

适用疾病: Prostate Cancer Metastatic；Prostate Cancer；CRPC
干预: Enhertu
地点: United States
申办方: Washington D.C. Veterans Affairs Medical Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06582628

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

适用疾病: Metastatic Prostate Cancer
干预: Enzalutamide capsule，Enzalutamide capsule and Talazoparib capsule
地点: Spain
申办方: Fundacion Oncosur

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT07210086

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

适用疾病: Prostate Cancer
干预: ADT，ARSI，No ADT/ARSI -decline
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07181161

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: AZD0516，AZD9574
地点: United States，Brazil，China，France 等 6 个
申办方: AstraZeneca

即将招募 EARLY / Phase 1 Dietary_Supplement药物

clinicaltrials.gov NCT07389174

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

适用疾病: mHSPC；mHNPC；Prostate Cancer Adenocarcinoma
干预: Standard Endocrine Therapy，LC-K76
地点: China
申办方: Shanghai Changzheng Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT07611110

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: AZD2265，Cabazitaxel，Abiraterone，Enzalutamide
地点: United States，Australia，Austria，Brazil 等 13 个
申办方: AstraZeneca

正在招募 Phase 2 药物

clinicaltrials.gov NCT07562438

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

适用疾病: Prostate Cancer
干预: 177Lu-P17-088
地点: China
申办方: First Affiliated Hospital of Fujian Medical University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06126731

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: Enzalutamide 40mg，Amoxicillin 500mg，Metronidazole 400mg，Vancomycin 125mg
地点: Switzerland，United Kingdom
申办方: Institute of Cancer Research, United Kingdom

正在招募 Phase 3 药物

clinicaltrials.gov NCT07333066

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

适用疾病: Metastatic Hormone-sensitive Prostate Cancer
干预: Apalutamide (Erleada™) 60 mg or 240 mg tablets，Docetaxel
地点: France，Germany，Italy，Portugal 等 1 个
申办方: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06780670

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

适用疾病: Prostate Cancer
干预: Investigators choice of SoC，AAA817，AAA817，AAA817
地点: United States，Australia，Brazil，China 等 8 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

clinicaltrials.gov NCT07096128

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

适用疾病: mCRPC
干预: [177Lu]Lu-PSMA-XT
地点: China
申办方: Jinming Zhang

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT05691465

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

适用疾病: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation；Metastatic Prostate Neuroendocrine Carcinoma；Metastatic Prostate Small Cell Neuroendocrine Carcinoma
干预: Biospecimen Collection，Computed Tomography，Gallium Ga 68-DOTATATE，Lutetium Lu 177 Dotatate
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 药物

clinicaltrials.gov NCT06496581

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

适用疾病: Prostate Cancer Metastatic
干预: 177Lu-PMSA-617，Standard of Care
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物其他

clinicaltrials.gov NCT05352178

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

适用疾病: Prostate Cancer；Prostate Cancer Recurrent；Prostate Cancer Metastatic
干预: Radiotherapy (SBRT) and/or surgery (metastasectomy)，Androgen deprivation therapy，Androgen receptor targeted therapy
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 3 药物

clinicaltrials.gov NCT03903835

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)；Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: Enzalutamide Oral Capsule，Abiraterone Oral Tablet，Carboplatin，Cabazitaxel 60 mg Solution for Injection
地点: Belgium，Norway，Sweden，Switzerland
申办方: Karolinska Institutet

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06457919

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

适用疾病: Prostate Cancer
干预: Tinengotinib，abiraterone acetate with prednisone，Enzalutamide
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 3 手术/操作放疗

clinicaltrials.gov NCT06585007

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

适用疾病: Castration-resistant Prostate Cancer；Oligoprogressive
干预: Radiotherapy，metastasectomy
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07206056

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

适用疾病: Progressive Metastatic Castrate Resistant Prostate Cancer
干预: Tulmimetostat DL1 QD，Tulmimetostat DL2 QD，Tulmimetostat DL3 QD，Tulmimetostat Doses 1 or 2 QD
地点: United States，Australia，Canada，China 等 10 个
申办方: Novartis Pharmaceuticals

即将招募 Phase 2 药物

clinicaltrials.gov NCT07164794

Memantine Hydrochloride in Prostate Cancer Patients

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)；Prostate Cancer；Neuroendocrine Prostate Cancer (NEPC)
干预: Memantine Hydrochloride
地点: 未列出
申办方: Bin Xu

正在招募 Phase 2 药物

clinicaltrials.gov NCT07476001

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Testosterone cypionate (Tc)，ADT with Luteinizing hormone-releasing hormone (LHRH) analog，PSMA-617
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT04729114

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

适用疾病: Prostate Cancer；Metastatic Castration Resistant Prostate Cancer；Metastatic Castration-sensitive Prostate Cancer
干预: PRL-02 injection，prednisone，dexamethasone，enzalutamide
地点: United States，Puerto Rico
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07230106

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

适用疾病: Prostate Cancer
干预: HS-20093 for Injection，SHR3680 Tablet，Abiraterone Tablet，SHR2554 Tablet
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05766371

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

适用疾病: Castrate Resistant Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Prostate Cancer
干预: Pembrolizumab，177Lu-PSMA-617
地点: United States
申办方: University of California, San Francisco

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07667400

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

适用疾病: Head and Neck Cancer；Head and Neck Squamous Cell Carcinoma；Paranasal Sinus Neoplasms
干预: SX-682，DTX
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 1 药物

clinicaltrials.gov NCT07244393

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: Lutetium (177Lu) DGUL，Pembrolizumab
地点: 未列出
申办方: Cellbion Co., Ltd.

正在招募 Phase 3 其他手术/操作

clinicaltrials.gov NCT06563388

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

适用疾病: Oligometastasis；Lung Cancer；Colo-rectal Cancer
干预: Stereotactic Ablative Radiotherapy，Best Practice
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT05413421

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: ORIC-944，Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets，Apalutamide (Erleada™) 60 mg or 240 mg tablets，Darolutamide (Nubeqa®) 300 mg tablets
地点: United States，Australia，Spain，United Kingdom
申办方: ORIC Pharmaceuticals

即将招募 Phase 1 药物

clinicaltrials.gov NCT07636707

QLF4113 in Participants With Metastatic Prostate Cancer

适用疾病: Prostate Cancer
干预: QLF4113 for injection
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

适用疾病: Cancer；Colorectal Cancer；Solid Tumor
干预: FOG-001，mFOLFOX-6，Nivolumab，Trifluridine/tipiracil
地点: United States，Australia
申办方: Parabilis Medicines, Inc.

正在招募 Phase 3 药物其他放疗

clinicaltrials.gov NCT05448547

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

适用疾病: Prostate Cancer
干预: Radiotherapy or surgery，initial observation，Hormone therapy
地点: Denmark，Finland，Norway，Sweden
申办方: Sven Löffeler

正在招募 Phase 2, Phase 3 药物放疗

clinicaltrials.gov NCT07426094

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

适用疾病: Prostate Cancer；Brachytherapy；Stereotactic Body Radiation Therapy (SBRT)
干预: Ultrahypofractionated Whole-Pelvis Radiotherapy，SBRT-Based Prostate Radiotherapy (No Boost)，Ablative Prostate Boost，Intermediate Nodal Dose Escalation
地点: Poland
申办方: Affidea Nu-med Center of Oncological DIagnostics and Therapy

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06615752

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: green tea and quercetin + docetaxel，Placebo + docetaxel
地点: United States
申办方: Charles Drew University of Medicine and Science

正在招募 Phase 1, Phase 2 诊断检测药物

clinicaltrials.gov NCT05413850

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；mCRPC
干预: Lutetium (177Lu) rhPSMA-10.1 Injection，18F-rhPSMA-7.3 injection (in phase 1 only)
地点: United States，Belgium，Germany，Netherlands 等 1 个
申办方: Blue Earth Therapeutics Ltd

正在招募 Phase 3 药物

clinicaltrials.gov NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: BMS-986365，Enzalutamide，Abiraterone，Docetaxel
地点: United States，Argentina，Australia，Austria 等 22 个
申办方: Celgene

正在招募 Phase 1 药物

clinicaltrials.gov NCT07080242

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

适用疾病: Small Cell Lung Cancer Metastatic or Locally Advanced；Neuroendocrine Cancer；Metastatic Neuroendocrine Prostate Cancer
干预: BL-M14D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 3 药物手术/操作

clinicaltrials.gov NCT06470243

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

适用疾病: Castration-Resistant Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biospecimen Collection，Bone Scan，Cabazitaxel，Carboplatin
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT05168618

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Atezolizumab，Cabozantinib S-malate
地点: United States
申办方: University of Utah

正在招募 Phase 1 药物

clinicaltrials.gov NCT06826768

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

适用疾病: Prostate Cancer
干预: REGN5678，Cemiplimab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06922318

The COSMYC Trial (COmbined Suppression of MYC)

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: ZEN-3694，Testosterone cypionate，Enzalutamide，Luteinizing hormone-releasing hormone (LHRH) analogue
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT05404139

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

适用疾病: Metastatic Prostate Cancer
干预: Enzalutamide，Standard of Care SBRT and ADT
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物

clinicaltrials.gov NCT06972628

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Prostate Cancer Patients With Bone Metastasis；Prostate Cancer (CRPC)
干预: Administering Lutetium-177-PSMA-617 (PLUVICTO)
地点: United States
申办方: Ebrahim S Delpassand

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07285694

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

适用疾病: Metastatic Castration Resistant Prostate Cancer (mCRPC)
干预: AB-3028
地点: United States
申办方: Arsenal Biosciences, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06217822

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

适用疾病: Advanced Metastatic Castration-resistant Prostate Cancer；Prostate Specific Membrane Antigen (PSMA) Expression
干预: 225Ac-PSMA-Trillium (BAY3563254)
地点: United States，Belgium，Canada，Finland 等 6 个
申办方: Bayer

正在招募 Phase 1, Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT04086290

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

适用疾病: Prostate Cancer Metastatic
干预: RARP，SBRT，ADT
地点: Denmark
申办方: Peter Busch Østergren

正在招募 Phase 1 药物

clinicaltrials.gov NCT05942001

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

适用疾病: Advanced Prostate Cancer
干预: HRS-5041
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07621692

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

适用疾病: Metastatic Castration Resistant Prostate Cancer (mCRPC)
干预: 161Tb-PSMA-I&T
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06629779

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

适用疾病: Metastatic Castration-Resistant Prostate Cancer
干预: PF-06821497，Placebo，Enzalutamide
地点: United States，Argentina，Brazil，Bulgaria 等 23 个
申办方: Pfizer

正在招募 Phase 1 药物

clinicaltrials.gov NCT05176483

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

适用疾病: Renal Cell Carcinoma (RCC)；Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Urothelial Carcinoma (UC)
干预: Zanzalintinib，Nivolumab，Ipilimumab，Nivolumab
地点: United States，Australia，Austria，Belgium 等 9 个
申办方: Exelixis

正在招募 Phase 2 放疗

clinicaltrials.gov NCT07038304

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

适用疾病: Prostate Cancer (Adenocarcinoma)；OligoProgressive Metastatic Disease；Castration Resistant Metastatic Prostate Cancer
干预: Metastasis directed radiotherapy
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07192614

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

适用疾病: Prostate Cancer
干预: AZD6621
地点: United States，Belgium，Canada，China 等 5 个
申办方: AstraZeneca

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT07641049

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

适用疾病: Metastatic Castration-resistant Prostate Cancer；Advanced Prostate Adenocarcinoma；PSCA-positive Prostate Cancer
干预: ETB-DualNK-01，Fludarabine，Cyclophosphamide
地点: China
申办方: Beijing Biotech

正在招募 Phase 2 药物

clinicaltrials.gov NCT07111507

A Study of Tarlatamab for People With Prostate Cancer

适用疾病: Metastatic Prostate Cancer
干预: Tarlatamab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT05800665

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

适用疾病: Advanced Prostate Cancer；Metastatic Prostate Cancer
干预: RO7656594
地点: United States，Australia，Canada，France 等 3 个
申办方: Genentech, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04868604

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

适用疾病: Prostatic Neoplasms, Castration-Resistant
干预: 64Cu-SAR-bisPSMA，67Cu-SAR-bisPSMA
地点: United States
申办方: Clarity Pharmaceuticals Ltd

即将招募 EARLY / Phase 1 器械药物

clinicaltrials.gov NCT07609225

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: 3'-Deoxy-3'-[18F]-fluorothymidine，Chemical-shift-encoded MRI
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT04242017

Long-term Better Than Short-term ADT With Salvage RT

适用疾病: Prostate Cancer
干预: Triptoreline
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 EARLY / Phase 1 Dietary_Supplement其他手术/操作

clinicaltrials.gov NCT05045066

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

适用疾病: Localized Prostate Carcinoma；Stage IV Prostate Cancer AJCC v8；Locally Recurrent Prostate Carcinoma
干预: Cholecalciferol，Quality-of-Life Assessment，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

即将招募 Phase 2 药物

clinicaltrials.gov NCT07592910

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)；Prostate Cancer (Adenocarcinoma)
干预: Mevrometostat，Enzalutamide
地点: 未列出
申办方: Prostate Cancer Clinical Trials Consortium

即将招募 Phase 2 药物

clinicaltrials.gov NCT06500247

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

适用疾病: The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
干预: Dalpicilib，Abiraterone Acetate (II)，Androgen Deprivation Therapy，Prednisone
地点: China
申办方: Qilu Hospital of Shandong University

正在招募 Phase 3 药物

clinicaltrials.gov NCT05974774

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

适用疾病: Prostate Cancer
干预: iMAB，cMAB
地点: Denmark，France，Spain
申办方: European Organisation for Research and Treatment of Cancer - EORTC

即将招募 Phase 2 药物

clinicaltrials.gov NCT07441837

Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients

适用疾病: Prostate Cancer
干预: Terbium 161- PSMA I&T
地点: Turkey (Türkiye)
申办方: Ankara University

正在招募 Phase 2 药物

clinicaltrials.gov NCT03522064

Bipolar Androgen Therapy + Carboplatin in mCRPC

适用疾病: Castration-resistant Prostate Cancer；Homologous Recombination Deficiency
干预: Testosterone Enanthate 100 MG/ML Injectable Solution，Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 2 药物

clinicaltrials.gov NCT07093866

Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study

适用疾病: mCRPC
干预: Disitamab Vedotin (RC48)，Abiraterone + prednisone
地点: China
申办方: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04503265

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

适用疾病: Advanced Malignant Neoplasm；Breast Cancer；Ovarian Cancer
干预: AMXI-5001:Dose Escalation Phase I，AMXI-5001:Dose Expansion Phase II
地点: United States
申办方: AtlasMedx, Incorporated

正在招募 Phase 3 药物

clinicaltrials.gov NCT06952803

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

适用疾病: Prostate Cancer
干预: Saruparib，Placebo，Abiraterone + Prednisolone/Prednisone，Androgen Deprivation Therapy (ADT)
地点: United States，Argentina，Australia，Austria 等 24 个
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06380660

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

适用疾病: Solid Tumor, Adult；BRCA1 Mutation；BRCA2 Mutation
干预: ACE-86225106 tablet
地点: China
申办方: Acerand Therapeutics (Shanghai) Limited

正在招募 Phase 2 诊断检测药物放疗

clinicaltrials.gov NCT07393867

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

适用疾病: Intermediate Risk Prostate Cancer；High Risk Prostate Cancer；Prostate Cancer
干预: PSMA PET/CT，Androgen Deprivation Therapy (ADT) +/- bicalutamide，Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
地点: United States
申办方: Martin T. King, MD, PhD

正在招募阶段未标明放疗

clinicaltrials.gov NCT06508567

Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

适用疾病: Prostate Cancer Recurrent；Prostate Cancer
干预: High Dose Rate Brachytherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2, Phase 3 药物放疗

clinicaltrials.gov NCT06282588

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

适用疾病: Prostate Cancer
干预: Darolutamide，Darolutamide matched placebo，Radiotherapy，Zoladex 3.6Mg Implant
地点: Belgium
申办方: Cancer Research Antwerp

正在招募阶段未标明放疗

clinicaltrials.gov NCT05936736

24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer

适用疾病: Localized Prostate Carcinoma
干预: prostate SBRT
地点: Italy
申办方: IRCCS San Raffaele

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT04271579

Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

适用疾病: Prostate Cancer
干预: Salvage Lymphnode dissection
地点: Germany
申办方: Martini-Klinik am UKE GmbH

正在招募 Phase 2 药物

clinicaltrials.gov NCT05560659

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

适用疾病: Oligometastatic Prostate Cancer
干预: 177Lu-PSMA
地点: Australia，Israel
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 1 药物

clinicaltrials.gov NCT07082920

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

适用疾病: Prostatic Neoplasms
干预: JNJ-78278343，JNJ-95298177
地点: United States，United Kingdom
申办方: Janssen Research & Development, LLC

即将招募 Phase 2 放疗

clinicaltrials.gov NCT07291557

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

适用疾病: Prostate Cancer
干预: Prostate Only Radiation Therapy (PORT)，Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT06574880

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

适用疾病: Malignant Neoplasm of Prostate；Locally Advanced Prostate Cancer
干预: Lu-PSMA-617，5-fraction Stereotactic Body Radiation Therapy (SBRT)
地点: United States
申办方: Angela Y. Jia, MD PhD

正在招募阶段未标明放疗

clinicaltrials.gov NCT05328505

Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer

适用疾病: Prostate Cancer
干预: Image-guided Radiotherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06776172

Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

适用疾病: Prostate Cancer Surgery；Prostate Cancers
干预: Extended Pelvic Lymph Node Dissection
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 2 药物

clinicaltrials.gov NCT06220188

PSMA-RLT in Biochemically Recurrent PCa

适用疾病: Prostate Cancer Recurrent
干预: [177Lu]Lu-PSMA I&T
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 2 放疗

clinicaltrials.gov NCT05010343

Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer

适用疾病: Localized Prostate Cancer
干预: carbon ion irradation，Carbon Ion Irradiation With SIB
地点: China
申办方: Shanghai Proton and Heavy Ion Center

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT05354375

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

适用疾病: Immunotherapy
干预: CAR-T cell immunotherapy
地点: China
申办方: The Affiliated Hospital of Xuzhou Medical University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05616650

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

适用疾病: Prostatic Neoplasms；Prostate Cancer；Prostate Adenocarcinoma
干预: 18F-DCFPyL，Stereotactic Body Radiation Therapy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07129551

Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery

适用疾病: Prostate Cancer (Adenocarcinoma)
干预: preop virtual 3D model，postop 3D model
地点: Germany
申办方: Martini-Klinik am UKE GmbH

正在招募阶段未标明器械诊断检测放疗

clinicaltrials.gov NCT04035642

Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)

适用疾病: Prostate Cancer
干预: IGRT-VMAT / SDRT 24 Gy in 1 fraction，Rectal balloon with air filling，Urethral catheter loaded with beacon transponders，PSMA PET/CT for DIL definition and/or staging where protocol-required
地点: Portugal
申办方: Fundacao Champalimaud

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT07272317

PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial

适用疾病: Prostate Cancer
干预: experimental group (navigation-assisted RARP)
地点: China
申办方: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT06625970

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

适用疾病: High Risk Prostate Carcinoma；Prostate Cancer
干预: Darolutamide，Stereotactic Body RadioTherapy (SBRT)，ADT (Standard of Care)，radiotherapy
地点: France，Martinique
申办方: UNICANCER

正在招募 Phase 1 药物

clinicaltrials.gov NCT04104607

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

适用疾病: Castration-Resistant Prostatic Cancer
干预: CC-1, PSMAxCD3
地点: Germany
申办方: University Hospital Tuebingen

正在招募 EARLY / Phase 1 药物放疗

clinicaltrials.gov NCT03861676

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

适用疾病: Prostate Cancer
干预: Focal brachytherapy with PSMA PET imaging，(18F)DCFPyL
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

clinicaltrials.gov NCT06758882

Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET

适用疾病: High Risk Prostate Cancer
干预: Apalutamide，Androgen receptor (AR) inhibitor
地点: Italy
申办方: Marco Oderda

正在招募 Phase 2 药物

clinicaltrials.gov NCT05155046

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

适用疾病: Localized Prostate Cancer
干预: 18F-DCFPyL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT04402151

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

适用疾病: Prostate Cancer
干预: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC，Stereotactic Body Radiation Therapy (SBRT)
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06441994

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

适用疾病: Prostate Cancer
干预: PSW-1025
地点: Japan
申办方: Osaka University

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06392295

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

适用疾病: Prostate Cancer；Prostate Adenocarcinoma；Hormone Sensitive Prostate Cancer
干预: Para Aortic Radiation Therapy: Photon Therapy，Para Aortic Radiation Therapy: Proton Therapy，Androgen Deprivation Therapy，Androgen Receptor Signaling Inhibitor
地点: United States
申办方: University of Miami

正在招募 Phase 2 药物其他手术/操作

clinicaltrials.gov NCT07025369

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

适用疾病: Prostate Adenocarcinoma；Stage IIC Prostate Cancer AJCC v8；Stage III Prostate Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Flotufolastat F-18 Gallium，Laparoscopic Radical Prostatectomy with Robotics
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 生物制剂

clinicaltrials.gov NCT06549465

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

适用疾病: PSMA PET-Positive Castration-Resistant Prostate Cancer
干预: In-111 rosopatamab tetraxetan，45 kBq/kg Ac-225 rosopatamab tetraxetan，55 kBq/kg Ac-225 rosopatamab tetraxetan，60 kBq/kg Ac-225 rosopatamab tetraxetan
地点: United States
申办方: Convergent Therapeutics

正在招募 Phase 2 放疗

clinicaltrials.gov NCT07234981

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

适用疾病: Prostate Cancer
干预: PSMA-guided Salvage Radiation
地点: United States
申办方: University of Nebraska

即将招募 Phase 2 药物放疗

clinicaltrials.gov NCT07550517

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

适用疾病: High-Risk Localized Prostate Cancer
干预: EBRT + 6 mo ADT + 177Lu-PSMA-617，EBRT + 24 mo ADT
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07208240

Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

适用疾病: High Risk Prostate Cancer
干预: Tb-PSMA-I&T (Tb-PSMA)
地点: Israel
申办方: Rabin Medical Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT06259123

Neoadjuvant PSMA-RLT in Oligometastatic PCa

适用疾病: Prostate Cancer
干预: [177Lu]Lu-PSMA I&T
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 1 药物

clinicaltrials.gov NCT06044857

PSMA PET Response Guided SabR in High Risk Pca

适用疾病: Prostate Adenocarcinoma
干预: 68-Ga PSMA11
地点: United States
申办方: University of Texas Southwestern Medical Center

即将招募 Phase 2 药物

clinicaltrials.gov NCT07387510

PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows

适用疾病: Prostate Cancer Patients Undergoing Radical Prostatectomy
干预: 12 h before RP，24 h before RP，36 h before RP
地点: China
申办方: Haitao Niu, MD

正在招募 Phase 3 联合产品放疗

clinicaltrials.gov NCT04794777

Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer

适用疾病: Prostate Cancer
干预: Individualised therapy，Standard salvage therapy
地点: Sweden
申办方: Stefan Carlsson

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07237269

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

适用疾病: Prostate Cancer
干预: Androgen Deprivation Therapy (ADT)，Abiraterone，Prednisone，Radiation Therapy
地点: United States
申办方: University of Nebraska

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT04175431

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

适用疾病: Prostate Adenocarcinoma
干预: Positron Emission Tomography，Lymphadenectomy，Radiation Therapy，Abiraterone Acetate
地点: United States
申办方: University of Washington

正在招募 Phase 2 诊断检测药物手术/操作

clinicaltrials.gov NCT07455903

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

适用疾病: Prostate Cancer；Localized Prostate Carcinoma
干预: Leuprolide，Degarelix，Relugolix，Triptorelin
地点: United States
申办方: Baptist Health South Florida

正在招募 Phase 3 放疗

clinicaltrials.gov NCT04642027

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

适用疾病: Prostate Cancer；Cancer Recurrence
干预: Conventional sEBRT，Hypofractionated sEBRT
地点: Netherlands
申办方: University Medical Center Groningen

即将招募 Phase 2 药物

clinicaltrials.gov NCT07415135

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

适用疾病: Prostate Cancer
干预: 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery，0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery，0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery
地点: 未列出
申办方: Zhu Yinjie

正在招募 Phase 1 药物

clinicaltrials.gov NCT05656573

CART-PSMA Cells for Advanced Prostate Cancer

适用疾病: Prostate Cancer
干预: CART-PSMA cells
地点: China
申办方: Nova Therapeutics LLC

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07580196

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

适用疾病: Prostate Cancer
干预: Unilateral Extended Pelvic Lymph Node Dissection，Bilateral Extended Pelvic Lymph Node Dissection
地点: Italy
申办方: University of Turin, Italy

正在招募 Phase 1 药物

clinicaltrials.gov NCT06095089

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

适用疾病: Prostatic Neoplasms
干预: JNJ-78278343，JNJ-87189401，Apalutamide，Lutetium Lu-177 Vipivotide Tetraxetan
地点: United States，Australia，France，Japan
申办方: Janssen Research & Development, LLC

即将招募 Phase 1 药物

clinicaltrials.gov NCT07657806

DEC003M in Prostate Cancer

适用疾病: Advanced Prostate Cancer
干预: DEC003M
地点: China
申办方: Hangzhou DAC Biotechnology Co., Ltd.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT05893381

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

适用疾病: Prostate Cancer
干预: [177Lu]Lu-PSMA I&T，Stereotactic Radiotherapy
地点: Italy
申办方: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

正在招募 Phase 2 药物

clinicaltrials.gov NCT06449781

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

适用疾病: Prostate Cancer
干预: Lutetium (177Lu) vipivotide tetraxetan
地点: Poland
申办方: Maria Sklodowska-Curie National Research Institute of Oncology

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06085664

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

适用疾病: Prostate Cancer；Radical Prostatectomy
干预: REGN5678，Piflufolastat F18
地点: United States
申办方: M.D. Anderson Cancer Center

术语	中文意思	对找临床试验有什么用
mCRPC	转移性去势抵抗性前列腺癌，指在低睾酮状态下仍进展的转移性疾病。	海外前列腺癌试验非常常见的入组类别。
mCSPC	转移性去势敏感性前列腺癌。	和 mCRPC 是不同阶段，搜索和入组条件要区分。
BRCA / HRR mutation	DNA 修复相关基因改变。	可以找 PARP 抑制剂或 DNA repair 相关试验。
PSMA	前列腺特异性膜抗原，是影像和放射性配体治疗的重要靶点。	可以找 PSMA radioligand therapy、PSMA PET 相关试验。
Androgen receptor	雄激素受体通路是前列腺癌治疗核心方向之一。	可以找 AR inhibitor、androgen receptor pathway 相关试验。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

前列腺癌

当前同步到的治疗类试验